Searchable abstracts of presentations at key conferences in endocrinology

ea0094p301 | Thyroid | SFEBES2023

Thyroid eye disease manifestation following radioactive iodine treatment in patients with Graves’ disease

Truong Vi , Slater Deborah , Dhage Shaishav , Adam Safwaan

Background: Thyroid eye disease (TED) is common among patients with GravesÂ’ disease (GD), with an estimated prevalence of 25-58%. While radioactive iodine (RAI) therapy is effective in managing GD, there are concerns regarding the risk of TED after RAI. Therefore, studying the effects of RAI on TED is essential for improving clinical decision-making. Aim: To determine the incidence of the development or exacerbation...

ea0070aep1037 | Hot topics (including COVID-19) | ECE2020

Management of glucose profile throughout strict COVID-19 lockdown by patients with type 1 Diabetes prone to hypoglycemia using sensor-augmented pump

Viñals Clara , Mesa Alex , Roca Daria , Vidal Mercè , Pueyo Irene , Conget Ignacio , Giménez Marga

Aims: Spain has been one of the worst affected countries by the COVID-19 pandemic. A very strict lockdown at home was imposed with a tough restriction of mobility. We aimed to evaluate the impact of this exceptional scenario on glucose profile of patients with type 1 diabetes (T1D) prone to hypoglycemia using sensor-augmented pump (SAP).Methods: Patients with T1D prone to hypoglycemia using SAP (640G Medtronic Minimed) for at least 6 months under the fun...

ea0070aep1050 | Hot topics (including COVID-19) | ECE2020

The impact of strict COVID-19 lockdown in spain on glycemic profiles in patients with type 1 Diabetes prone to hypoglycemia using standalone continuous glucose monitoring

Mesa Alex , Viñals Clara , Pueyo Irene , Roca Daria , Vidal Mercè , Giménez Marga , Conget Ignacio

Aims: Spain has been one of the worst affected countries by the COVID-19 pandemic. A very strict lockdown at home was imposed with a tough restriction of mobility. We aimed to evaluate the impact of this exceptional scenario on glucose profile of patients with type 1 diabetes (T1D) prone to hypoglycemia using standalone continuous glucose monitoring.Methods: Patients with T1D prone to hypoglycemia using multiple daily injections and either a Dexcom G5 or...

ea0070aep625 | Pituitary and Neuroendocrinology | ECE2020

Malignant insulinoma treated with 177Lu-DOTATATE: Results in the first year post-therapy

Concepción Terroba-Larumbe María , Maria Palacio-Mures Jose , Crespo-Soto Cristina , Perez-Saborido Baltasar , Crespo-Herrero Guillermo , Ventosa-Viña Marta , Acuña-Garcia Manuel , Alejo-Ramos Mirian , Anacabe-Goyogana Itziar , Cuellar-Olmedo Luis

Introduction: Neuroendocrine tumors (NETs) are rare and their clinical behavior and prognosis correlates with mitotic rate and Ki-67 index. Most patients with advanced NET have liver metastases unresectable and somatostatin analogues are the initial therapy of choice but when disease progresses despite treatment and there are positive somatostatin receptors, peptide receptor radioligand therapy (PRRT), using lutetium-177, is a therapeutic option.Clinical...

ea0070ep372 | Pituitary and Neuroendocrinology | ECE2020

Pasireotide therapy in a patient with pituitary macroadenoma and asymptomatic acromegaly resistant to first generation somatostatin analogues

Concepción Terroba-Larumbe María , Palacio-Mures Jose Maria , Crespo-Soto Cristina , Ventosa-Viña Marta , Cuellar-Olmedo Luis , Acuña-Garcia Manuel , Anacabe-Goyogana Itziar , Areli Ticona-Spinoza Danay , Maria Delgado-Sanz Jose , Angel Rodriguez Garcia Javier

Introduction: Acromegaly increases morbidity and mortality and should be treated even in the asymptomatic phase. It is almost always caused by a GH-producing pituitary adenoma and although transsphenoidal surgery is the treatment of choice in most cases, in others, primary medical therapy is indicated.Clinical case: A 36-year-old female with a family history of thyroid functional pathology and diagnosed with micronodular goiter was evaluated in February ...

ea0070aep331 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Clinical and metabolic benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) therapy in diabetic patients with psychiatric comorbidities

Concepción Terroba-Larumbe María , Crespo-Soto Cristina , Palacio-Mures Jose Maria , Gonzalez-Sagrado Manuel , Conde-Vicente Rosa , Ventosa-Viña Marta , Peña-Lozano Silvia , Portela-Martin Ainara , Fernandez-Nuñez Marta , Calleja-Barnada Mar , Cuellar-Olmedo Luis

Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) therapyhas proven effective in type 2 diabetes but there is little data on its effect in patients with psychiatric comorbidity, who usually present worse metabolic and clinical control. The aim of this study was to evaluate if there are differences in the effect of this therapy in relation to the presence of these pathologies.Methods: 225 patients included in a therapy protocol with SGLT2i,...